Plenary Session
386 episodes - English - Latest episode: 12 days ago - ★★★★★ - 722 ratingsA podcast on medicine, oncology, & health policy.
Host: Vinay Prasad, MD MPH from University of California San Francisco.
Tweet your feedback to @Plenary_Session or e-mail [email protected]
Homepage Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
Episodes
1.35 BONUS! Conflict of Interest in Oncology
January 10, 2019 23:03 - 45 minutes - 43.1 MBThis BONUS episode is the recording of a lecture given to the Bioethics Study Group at OHSU on January 9, 2019 on conflict of interest, specifically in the field of oncology. Backers of our Patreon will be sent accompanying slides. Back us on Patreon! www.patreon.com/plenarysession
1.34 Endpoints in ECOG-ACRIN 2511, Update to KEYNOTE-024, & Mentorship with Dr. Joseph Shatzel
January 10, 2019 16:53 - 1 hour - 69.1 MBIn this episode, we discuss two recent papers published in the Journal of Clinical Oncology: ECOG-ACRIN 2511 and the update adding overall-survival and crossover results to KEYNOTE-024. We end with an interview with Dr. Joseph Shatzel of OHSU on mentorship. ECOG-ACRIN 2511: http://doi.org/10.1200/JCO.18.00264 KEYNOTE-024 update: http://doi.org/10.1200/JCO.18.00149 Back us on Patreon! www.patreon.com/plenarysession
1.33 Guarantee-Time Bias & Trials, Philanthropy, and Cancer Research with Dr. Tom Beer
January 05, 2019 00:07 - 1 hour - 88.3 MBIn this episode we discuss guarantee-time bias in the context of the recent JAMA Oncology paper titled "Profiling Preexisting Antibodies in Patients Treated With Anti–PD-1 Therapy for Advanced Non–Small Cell Lung Cancer". We also have an interview with Dr. Tom Beer, the Deputy Director of the OHSU Knight Cancer Institute, on clinical trials, leadership, philanthropy, and future directions in cancer research. Profiling preexisting antibodies: doi.org/10.1001/jamaoncol.2018.5860 Back us on Pa...
1.32.1 Radiation Oncology with Dr. Brian Kavanagh
January 04, 2019 20:51 - 1 hour - 70.1 MBEpisode 1.32 ran a little long, so this is episode 1.32.1 - we broke out the interview with Dr. Brian Kavanagh, the Chairman of Radiation Oncology at the University of Colorado, to make the interview more accessible. Back us on Patreon! www.patreon.com/plenarysession
1.32 Rating Metrics, Conflict of Interest in the News, & Radiation Oncology with Dr. Brian Kavanagh
January 03, 2019 00:19 - 1 hour - 118 MBThis week we discuss various academic indices including the h-index and the new Altmetric score, and we go over the recent NY Times article on conflict of interest. We end with an interview with Dr. Brian Kavanagh, the Chairman of Radiation Oncology at the University of Colorado. NY Times: https://www.nytimes.com/2018/12/31/upshot/congratulations-on-the-promotion-but-did-science-get-a-demotion.html Back us on Patreon! patreon.com/plenarysession
1.31 Ketogenic Diet, COMET-1 and COMET-2, the Health Insurance Marketplace with Dr. Jane Zhu
December 27, 2018 00:45 - 1 hour - 81.6 MBWe begin this episode with a discussion of Dr. Mukherjee's ongoing study combining a ketogenic diet with PI3 kinase inhibition. We continue with a take on a recent reanalysis of COMET-1 and COMET-2, two failed randomized controlled trials of cabozantinib versus prednisone or mitoxantrone-prednisone in metastatic castration-resistant prostate cancer. We end with an interview on instabilities in the health insurance marketplace with Dr. Jane Zhu of OHSU, an expert in the Affordable Care Act. K...
1.30 BONUS! Clinical Trial Endpoints, Drug Approval, Incentives in Oncology
December 19, 2018 17:02 - 1 hour - 61.8 MBThis BONUS episode is the recording of a lecture given to the National Breast Cancer Coalition on December 11, 2018. It's on clinical trial endpoints, FDA drug approval, and incentives in oncology. Backers of our Patreon will be sent accompanying slides. Back us on Patreon! www.patreon.com/plenarysession
1.29 RCT of Parachutes and Frameworks for Internal Medicine with Dr. Andre Mansoor
December 18, 2018 00:51 - 1 hour - 82.6 MBWe begin this episode with a critique of the recent paper in the BMJ, "Parachute use to prevent death and major trauma when jumping from aircraft: randomized controlled trial" and we end it with an interview with Dr. Andre Mansoor, discussing his new book: "Frameworks for Internal Medicine." Parachutes: https://www.bmj.com/content/363/bmj.k5094 Back us on Patreon! https://www.patreon.com/plenarysession
1.28 Questionable FDA Drug Approvals and Building a Career with Dr. Chadi Nabhan
December 13, 2018 00:32 - 1 hour - 54.4 MBIn this episode we critique two recent FDA drug approvals (venetoclax in combination with azacitidine or decitabine or low-dose cytarabine; glasdegib in combination with low-dose cytarabine -- both for acute myeloid leukemia)and we interview Dr. Chadi Nabhan, the Chief Medical Officer of Cardinal Health, on career transitions. The interview was taped on location at the 2018 annual conference of the American Society of Hematology in San Diego.
1.27 BONUS! Medical Reversal
December 06, 2018 22:56 - 57 minutes - 42.6 MBThis BONUS episode is the recording of a lecture given to hospitalists at Kaiser Permanente on November 14, 2018. It's a slightly different version of the talk on medical reversals that we recorded for episode 1.16. Backers of our Patreon will be sent accompanying slides. Back us on Patreon: https://www.patreon.com/plenarysession
1.26 Lesson From an ASH Abstract, Behind the Scenes of a Residency Program with Dr. Sima Desai
December 04, 2018 22:27 - 1 hour - 55.7 MBHaving just returned from the 2018 American Society of Hematology (ASH) Annual Meeting, we begin this episode by discussing the abstract of a study that stretches its conclusions. We dedicate most of the episode to an interview with Dr. Sima Desai, the program director for OHSU's Internal Medicine Residency Program. She gives some great insight on the program's inner workings. ASH abstract: https://ash.confex.com/ash/2018/webprogram/Paper117448.html We have also launched our Patreon page! B...
1.25 Welch's Legacy, Interpreting NGS, Uncertainty over Pregabalin, Beyond EBM with Dr. Sam Edwards
November 27, 2018 22:15 - 1 hour - 81.3 MBIn this episode we discuss: Dr. Gilbert Welch's Wikipedia page and how we should keep his decades of work in perspective, a Twitter conversation between experts on differing interpretations of results from next-generation sequencing, the new paper in JAMA titled "Assessment of Pregabalin Postapproval Trials and the Suggestion of Efficacy for New Indications", and finally, along with Dr. Sam Edwards of OHSU, we criticize the recent perspective piece in NEJM titled "Beyond Evidence-Based Medici...
1.24 Useless Medical Conferences and Dr. Adam Obley on Vascepa, Fish Oil, Vitamin D and Methotrexate
November 20, 2018 00:28 - 50 minutes - 50.4 MBIn this episode we discuss John Ioannidis' article on the uselessness of medical conferences, published in JAMA: "Are Medical Conferences Useful? And for Whom?", followed by an interview with return-guest Dr. Adam Obley on a few recent clinical trials: Vascepa, fish oil, vitamin D, and methotrexate. Medical conferences: doi.org/10.1001/jama.2012.360
1.23 BONUS! Developing Technology with Fewer Reversals: Maybe We Need More Translation Failure
November 15, 2018 22:14 - 1 hour - 61.5 MBThis BONUS episode is the recording of a lecture given as part of the Biomedical Engineering Seminar series at Oregon Health & Science University on November 9, 2018. The talk is on how to move technological devices to the clinic with fewer reversals.
1.22 Elo-Pom-Dex, Immunotherapy Combos, Inherent Bias, and the FDA with Dr. Erick Turner
November 13, 2018 01:12 - 1 hour - 67.3 MBIn this episode, we tackle the recent papers in the New England Journal of Medicine on "Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma" and "Immunotherapy Combinations in Multiple Myeloma", as well as a comment in The Lancet Oncology's editorial "9 Weeks That Matter for Patients With Gastric Cancer". We conclude with an interview with Dr. Erick Turner of OHSU on the FDA, regulatory capture, selective reporting, and transparency. Elo-pom-dex: http://doi.org/10.1056/NEJMoa...
1.21 Nab-Paclitaxel in CCA, OS of PALOMA-3, Transparency, and Dr. Talal Hilal's Advice for Trainees
November 06, 2018 17:03 - 1 hour - 79.5 MBIn this episode we question the conclusions of the phase II trial "Nab-Paclitaxel and Gemcitabine as First-line Treatment of Advanced or Metastatic Cholangiocarcinoma", review the long-term overall survival results from PALOMA-3, discuss Dr. Gyawali et al.'s paper on the need for transparency in reporting harms from cancer drugs, and interview Dr. Talal Hilal from the Scottsdale Mayo Clinic on his advice for trainees. Nab-paclitaxel and gemcitabine: doi.org/10.1001/jamaoncol.2018.3277 Palboc...
1.20 Precision Oncology: Some Benefit, Mostly Hype and Mentorship with Dr. Andrae Vandross
October 30, 2018 21:06 - 1 hour - 144 MBWe begin this episode analyzing the unrepentant hype of precision oncology in a monologue that was originally one half of a debate titled: "Is Precision Oncology Generating Patient Benefit or Just Hype?" We conclude with an interview with Dr. Andrae Vandross on the mentor/mentee relationship.
1.19 BONUS! Introduction to Cancer Drug Policy
October 26, 2018 17:41 - 49 minutes - 71.1 MBThis BONUS episode is the recording of a lecture given as part of a Cancer Intersession course for med students at Oregon Health & Science University on October 25, 2018. The talk is an introduction to cancer drug policy.
1.18 IMpassion130 and Hot-Spotting with Dr. Brian Chan
October 23, 2018 21:17 - 1 hour - 68.7 MBIn this episode we evaluate the IMpassion130 trial on the use of atezolizumab in triple-negative breast cancer. We also interview Dr. Brian Chan of OHSU on a randomized controlled trial he's running that tests whether Dr. Gawande's idea of "hot-spotting" -- tailoring interventions to medically complex patients -- does decrease hospitalizations. IMpassion130: doi.org/10.1056/NEJMoa1809615 Hot-spotting: https://www.newyorker.com/magazine/2011/01/24/the-hot-spotters
1.17 BONUS! Interpretation of Cancer Clinical Trials
October 22, 2018 22:03 - 1 hour - 73.9 MBThis BONUS episode is the recording of a two-part talk addressed to oncology fellows given at Oregon Health & Science University on October 5 and October 12, 2018. The talk is on how to interpret cancer clinical trials.
1.16 BONUS! Crowdsourcing Data Analysis and Medical Reversal: Why 40% of What We Do is Wrong
October 17, 2018 22:13 - 55 minutes - 56.3 MBThis BONUS episode is the recording of the Hospitalist Grand Rounds given at Oregon Health & Science University on October 11, 2018. The talk is on medical reversal. Before the talk we discuss the paper "Many Analysts, One Data Set: Making Transparent How Variations in Analytic Choices Affect Results" by Silberzahn et al., published in Advances in Methods and Practices in Psychological Science. Paper: doi.org/10.1177/2515245917747646
1.15 Minimally Effective Treatments, CheckMate 331, and Dr. Adam Obley on Low-Value Healthcare
October 16, 2018 20:23 - 1 hour - 116 MBIn this episode we review the recent paper in Nature Reviews Clinical Oncology by Booth, C.M. and Detsky, A.S. titled "Why patients receive treatments that are minimally effective?". We discuss the failure of CheckMate 331 to meet its primary endpoint despite having received accelerated FDA approval. Finally, we bring back Dr. Adam Obley (from episode 1.01) to talk about low-value healthcare, medical education, social media, and more!
1.14 BONUS! Immunotherapy in Desperation and the Pennington Lecture: Myths of Medicine and Marketing
October 12, 2018 19:19 - 56 minutes - 52.8 MBThis BONUS episode is the recording of the 22nd annual Pennington Lecture given at Oregon Health & Science University on September 21, 2018. The lecture is on seven myths of medicine and marketing. Before the lecture we read and discuss the editorial "Desperation Oncology" by Tito Fojo, published in Seminars in Oncology.
1.13 KEYNOTE-189, Dr. Talal Hilal on MRD, and Medical Education with Dr. Adam Cifu
October 08, 2018 23:50 - 1 hour - 101 MBListen in for a breakdown of the good and the bad of KEYNOTE-189(trial published in NEJM), a discussion with Dr. Talal Hilal of the Mayo Clinic on the rise of minimal residual disease as a clinical endpoint, and an interview with Dr. Adam Cifu of the University of Chicago Pritzker School of Medicine on medical education, sham trials, and more.
1.12 BONUS! Evidence-Based Medicine Has Been Hijacked in Oncology
October 03, 2018 23:57 - 37 minutes - 35.2 MBThis BONUS episode is the recording of a Grand Rounds talk given at Oregon Health & Science University on September 19, 2018. The talk was inspired by the article by JPA Ioannidis titled "Evidence-based medicine has been hijacked: a report to David Sackett", published May 2016 in the Journal of Clinical Epidemiology.
1.11 Peanut Gallery, Research Parasites, Appendectomies, HRQoL and PFS, Dr. Bishal Gyawali
October 02, 2018 22:55 - 1 hour - 116 MBWe discuss Dr. Califf's comment on the "social media peanut gallery of experts", Dr. Drazen's comment on "research parasites" and his retirement from NEJM, the recent paper in JAMA on long-term follow up for antibiotics as compared to appendectomies, and the paper in JAMA Internal Medicine on the relationship between health-related quality of life and progression-free survival. Finally, we interview Dr. Bishal Gyawali on a variety of topics, including cancer groundshot.
1.10 Criticism via Twitter, PACIFIC, PCI for CAD, and Dr. Rebecca Cooney of The Lancet
September 25, 2018 23:30 - 1 hour - 107 MBToday we tackle some cardiologists' opposition to criticizing clinical trials on Twitter, the PACIFIC trial on durvalumab in stage III non–small-cell lung cancer, and the recent paper in Heart: "Percutaneous Coronary Intervention for Stable Coronary Artery Disease" by R.K. Al-Lamee, A.N. Nowbar, and D.P. Francis. We end with an interview on academic medical publishing with Dr. Rebecca Cooney, North American Executive Editor of The Lancet.
1.09 Response Rate in Phase I trials, JACOB, and MI, Stroke, and Metastasis as Hard Endpoints
September 20, 2018 19:47 - 33 minutes - 52.4 MBSpecial episode! We discuss the recent correspondence in NEJM on response rate in phase I clinical trials, the JACOB trial published in The Lancet Oncology on pertuzumab for HER2-positive gastric cancer, and we give an evaluation of MI, stroke, and metastasis as hard endpoints.
1.08 Hyperprolific authors, NCCN with Jeff Wagner, and Dr. Renee Dversdal on Ultrasounds
September 14, 2018 23:53 - 1 hour - 94 MBIn this episode we discuss hyperprolific authors and the recent comment in Nature by JPA Ioannidis, R Klavans, & KW Boyack; NCCN guidelines with fourth-year medical student Jeffrey Wagner; and point-of-care ultrasounds with Dr. Renee Dversdal of OHSU.
1.07 Adjuvant Sunitinib in RCC, future of EBM with Dr. John Mandrola
September 11, 2018 20:38 - 1 hour - 92.4 MBIn this episode we discuss the USA FDA's recent approval of sunitinib as the adjuvant treatment for patients with resected renal cell carcinoma who are at high risk of relapse. We also interview cardiologist Dr. John Mandrola on new directions forward for evidence-based medicine.
1.06 RELEVANCE, Jenny Gill, and Dr. Catherine Livingston of the Oregon Health Authority
September 07, 2018 20:12 - 1 hour - 123 MBIn this episode we break down the RELEVANCE trial published in the New England Journal of Medicine; discuss big data in observational studies with Jenny Gill, MS; and interview Dr. Catherine Livingston of OHSU, an expert in healthcare policy, on her work with the Oregon Health Authority and state Medicaid.
1.05 Cost and Efficacy of Cancer Drugs, ECHELON-1, Dr. Derrick Tao, and EBM with Dr. Martha Gerrity
September 05, 2018 21:43 - 1 hour - 93.5 MBIn this episode we cover the cost and efficacy of cancer drugs; review ECHELON-1; interview Dr. Derrick Tao of OHSU about his recent Lancet Oncology paper on poor control arms; and discuss evidence-based medicine with EBM expert and internist at OHSU, Dr. Martha Gerrity.
1.04: Nutritional Epi, Lenvatinib, Nivo and Ipi for Melanoma, and Dr. Avi O'Glasser
August 30, 2018 17:12 - 56 minutes - 85.3 MBThis week's episode is on nutritional epidemiology by JPA Ioannidis; lenvatinib for hepatocellular carcinoma; nivolumab and ipilimumab for melanoma; and #medtwitter with Dr. Avi O Glasser from OHSU.
1.03: RWE, Right to Try, Talazoparib, Nivolumab, and Dr. Andrae Vandross
August 21, 2018 23:07 - 1 hour - 151 MBWe're moving to our new format. We begin with a monologue of the most noteworthy articles in this week's news. We'll be talking about real-world evidence, Right to Try, talazoparib, and the FDA approval for nivolumab in small-cell lung cancer. In the second half of the show, we'll interview Dr. Andrae Vandross, a community oncologist at UCLA Medical Center.
1.02: HemOnc Fellowship and Hype in Cancer Medicine with Dr. Jeremy Cetnar
August 16, 2018 23:48 - 35 minutes - 32.3 MBIn episode 2, we discuss the fellowship program and then take a deep dive into hype surrounding cancer drugs. Our guest is Jeremy Cetnar, MD from Oregon Health & Science University.
1.01: Introduction and Dr. Adam Obley
August 14, 2018 23:22 - 47 minutes - 43.4 MBJoin us for an introduction to who we are and what our podcast is about, then stick around for a hard-hitting discussion of evidence-based medicine, randomized controlled trials, sham controls, and broad next-generation sequencing in cancer. Our guest is Adam Obley, an Assistant Professor of Medicine at Oregon Health & Science University.